Salestools LogoSalestools
Agentes IA de Salestools
Soluciones
Recursos
Empresa
Precios
Salestools Logo

Salestools

El agente IA #1 para equipos de ventas y Go-to-Market. Vende más, más rápido, con menos esfuerzo.

Producto

  • Agentes de ventas IA
  • Datos de intención
  • Datos tecnológicos
  • Seguimiento de visitantes
  • Co-Pilot
  • Venta social

Soluciones

  • Servicio al cliente
  • Comercio electrónico
  • SaaS
  • Empresarial
  • Pequeña empresa

Recursos

  • El informe
  • Documentación
  • Referencia de API
  • Centro de ayuda
  • Blog
  • Casos de estudio
  • Webinars

Empresa

  • Acerca de
  • Carreras
  • Prensa
  • Contacto
  • Socios

Nuestras ubicaciones

  • Nueva York, HQ
  • Bucarest, laboratorio de investigación IA
  • Zug, Suiza

© 2025 Salestools. Todos los derechos reservados.

Términos de datos y seguridadPolítica de privacidadTérminos de servicio
Todos los sistemas operativos
Salestools LogoSalestools
Agentes IA de Salestools
Soluciones
Recursos
Empresa
Precios
Back to The Report
Fundraising

Editas Medicine

Editas Medicine Raises $118M in Follow-on Offering

2013
Founded
300+
Employees
11 Hurley Street, Cambridge, MA 02141
Updated October 18, 2024
2 min read

Quick Facts

Editas Medicine Raises $118M in Follow-on Offering


Editas Medicine has successfully raised $118M in a Follow-on Offering at a $1.8B valuation led by Polaris Partners, Flagship Pioneering, Third Rock Ventures, Google Ventures.


Company Overview


Editas Medicine is a Biotech company headquartered in 11 Hurley Street, Cambridge, MA 02141, founded in 2013 with 300+ employees.


Genome editing medicines


Fundraising Details


  • Amount Raised: $118M
  • Round Type: Follow-on Offering
  • Valuation: $1.8B
  • Date: 2024-10-18
  • Investors: Polaris Partners, Flagship Pioneering, Third Rock Ventures, Google Ventures

About Editas Medicine


Genome editing medicines The company is positioned in the Biotech sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 11 Hurley Street, Cambridge, MA 02141
  • Founded: 2013
  • Team Size: 300+
  • Industry: Biotech

What This Means


This funding round demonstrates strong investor confidence in Editas Medicine's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Editas Medicine's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $1.8B valuation marks an important milestone for Editas Medicine, positioning the company among notable players in the Biotech industry.


Looking Ahead


With this new capital, Editas Medicine is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-10-18. For more information about Editas Medicine, visit their headquarters at 11 Hurley Street, Cambridge, MA 02141.

Topics

Fundraising(2912)BiotechFollow-on OfferingEditas Medicine

About the Author

Fundraising News Team
Fundraising News Team
Tracking the latest funding rounds and investment news

Related Company Reports

Fundraising
Harvey AI

Harvey AI Raises $160 million in Series F

Harvey AI, a AI Software company based in San Francisco CA, has raised $160 million in Series F at a $8 billion valuation led by Andreessen Horowitz.

Market Intelligence Team
Market Intelligence Team
Dec 4, 2025
0 min read•160 million
Fundraising
7AI

7AI Raises $130 million in Series A

7AI, a Cybersecurity company based in Boston MA, has raised $130 million in Series A at a $700 million valuation led by Index Ventures.

Market Intelligence Team
Market Intelligence Team
Dec 4, 2025
0 min read•130 million
Fundraising
TRIANA Biomedicines

TRIANA Biomedicines Raises $120 million in Series B

TRIANA Biomedicines, a Biotechnology company based in Lexington MA, has raised $120 million in Series B at a Undisclosed led by Ascenta Capital.

Market Intelligence Team
Market Intelligence Team
Dec 3, 2025
0 min read•120 million